Evidence map›Paper›PMID 27287037›Full record

ReviewClinical reviews in allergy & immunology2016

The Story of Angioedema: from Quincke to Bradykinin.

Avner Reshef, Mona Kidon, Iris Leibovich

Abstract readHistorical ArticleReview
PubMed Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 75 citations in OpenAlex.

  1. Case Report: Hereditary Angioedema Accompanied by Chronic Spontaneous Urticaria.Clinical, cosmetic and investigational dermatology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Systemic lupus erythematosus with various clinical manifestations in a patient with hereditary angioedema: a case report.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022
    Article
  9. The Enigma of Prodromes in Hereditary Angioedema (HAE).Clinical reviews in allergy & immunology · 2021
    Review
  10. Article
  11. Article
  12. Recurrent angioedema: Experience at a tertiary care urban medical center.Laryngoscope investigative otolaryngology · 2021
    Article
  13. Article
  14. Lethal manifestations of angioedema.Forensic science, medicine, and pathology · 2019
    Article
  15. Article
  16. Article
  17. The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.Clinical reviews in allergy & immunology · 2016
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Avner ReshefAngioedema Center, Allergy & Clinical Immunology, Sheba Medical Center, Tel Hashomer, Ramat Gan, 52621, Israel. areshef@shaba.health.gov.il.
Mona KidonSafra Pediatric Hospital, Sheba Medical Center, Tel Hashomer, Affiliated to Sackler Medical School, Tel Aviv University, Tel Aviv, Israel.
Iris LeibovichAngioedema Center, Allergy & Clinical Immunology, Sheba Medical Center, Tel Hashomer, Ramat Gan, 52621, Israel.
Sheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The term "swelling" has been used in the old scriptures to illustrate a change of normal figure and, as such, an expression of illness. It should be noted that in ancient times, human diseases were very often regarded a punishment from God. Hence, it is not surprising that one of the oldest tests for infidelity involved swelling as an inflicted punishment. The great Greek physician Hippocrates (377-460 BC), considered one of the most outstanding figures in the history of medicine and "Father of the Western Medicine," already used the term oídēma to describe swelling of organs. It took many centuries later until the first description of angioedema as a distinct medical entity was minted by Quinke in 1882. The historical progression in angioedema research has been characterized by intermittent "leaps" in interest and scientific achievements. As an example, it took 75 years from the accurate description of hereditary angioedema (HAE) by Osler (1888), until a group of researchers headed by Donaldson (1963) disclosed the central role of C1 inhibitor in angioedema pathophysiology. What followed was a result of a collective effort by many researchers and scientific groups who were able to elucidate the intricate connections between the implicated biochemical pathways. Still, scientific progress was hardly translated into effective therapy, and another 45 years had to elapse until the renewed interest in HAE was boosted by studies on the efficacy and safety of novel therapies about 10 years ago. In the twenty-first century, HAE ceased to be an "orphan disease" and its future is far more optimistic. It is better managed now by specialized angioedema centers, harmonized clinical guidelines, educational programs, laboratory services, and continued basic and clinical research. Patient associations worldwide are offering support and guidance, and governments and healthcare systems are gradually addressing patient and family needs.

Indexed as

AngioedemaAnimalsBradykininCombined Modality TherapyComplement C1 Inhibitor ProteinFibrinolysisGenetic Predisposition to DiseaseHistory, 15th CenturyHistory, 16th CenturyHistory, 17th CenturyHistory, 18th CenturyHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyHistory, AncientHistory, MedievalBradykininComplement C1 Inhibitor ProteinReceptors, BradykininAngioedemaBradykininClinical guidelinesComplementFibrinolysisHistoryProdromesSwelling

Identifiers

PMID27287037
OpenAlexW2416104447

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.